Research Study

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Psoriasis
ClinicalTrials.gov# 
NCT02931838
Status 
Recruiting
Study Start/End 
May 2, 2017 to Jan 7, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Sze Wai Ho, Study Coordinator
Phone 
604-875-5296
Email Address 
szewai.ho@ubc.ca
Purpose of Study 

To assess the safety and tolerability of multiple oral doses of BMS-986165 in subjects with moderate to severe psoriasis. To compare the proportion of subjects with moderate to severe psoriasis is experiencing a 75% improvement as measured by reduction in psoriasis area and severity index (PASI-75) score after 12 weeks of treatment between doses of BMS-986165 and placebo.  

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.